Ticker brief · 2026-08-23
TEM TEMPUS AI INC-CL A
Clinical validation and short covering overpower rising deal risk
Consumer, Non-cyclical · Healthcare-Products
Lean: bullishlast close
$64.04
1 day
-9.4%
14 days
+22.9%
mkt cap
$10.8B
signals 14d
463
authors 14d
162
crowd 14d
+1.0σfade
The tape and credible fundamental voices lean bullish as Moderna-Merck Phase 3 success validates TEM-linked personalized-oncology infrastructure. The key late-week shift was Personalis trading above the $16.25 offer, raising higher-bid or deal-break risk just as BTIG lifted its target to $80 from $70. Heavy call buying and 28.2%-33% short interest support further upside, but the squeeze structure and clustered trims near the 70s make the position vulnerable to sharp reversals.
BULL CAMP
Bulls view the Phase 3 cancer-vaccine result as commercial validation for TEM's sequencing, clinical-data and AI platform, with Personalis strengthening its oncology infrastructure. A volume-backed breakout, concentrated call demand and high short interest reinforce the fundamental rerating.
Key voices@StockSavvyShayHIGHB-2.15@cevikfinanceMEDIUM-HIGHC-1.35@MMMTwealthMEDIUM-HIGHA-2.56@JaguarAnalyticsMEDIUM-HIGHB+0.35@ArtofSpecuyckyMEDIUMB+0.68
“MRNA's breakthrough expands personalized medicine demand and benefits TEM's sequencing, monitoring and clinical-data platform.”— @StockSavvyShay · tweet ↗
BEAR / SKEPTIC
Bears focus on Personalis trading above TEM's $16.25 offer, implying a higher required payment or transaction failure. Prospective equity financing and technical resistance after a 45%-plus surge add dilution and reversal risk.
Key voices@LogicalThesisMEDIUM-HIGHA+2.21@SixSigmaCapitalMEDIUM-HIGHB-0.40@hiddensmallcapsMEDIUMB-0.77@ALEXEIMARTOVMEDIUM-HIGHA-0.74
“A failed transaction or higher Personalis consideration would be negative for TEM.”— @LogicalThesis · tweet ↗
Hypotheses12direction · basis · magnitude · supporters — NEW = first seen this week
▲The successful Moderna-Merck Phase 3 cancer-vaccine trial validates demand for TEM-linked sequencing, monitoring and personalized-oncology infrastructure.
@StockSavvyShayHIGHB-2.152s · insight@cevikfinanceMEDIUM-HIGHC-1.351s@PSInvestorLOW-MEDIUMB-1.482s@CaesarCapitalzLOW-MEDIUMC-0.811s@KoujiSato19MEDIUMC+1.082s@donaldjdeanMEDIUMC-0.091s+3 more
▲The $1.5B Personalis acquisition at $16.25 per share should deepen TEM's precision-oncology testing assets and strategic data advantage.
@MWM76LOW-MEDIUMC-1.004s@hiddensmallcapsMEDIUMB-0.772s · insight@Venu_7_MEDIUM-HIGHB+0.101s · insight@donaldjdeanMEDIUMC-0.091s@KoujiSato19MEDIUMC+1.081s@ScorEnterprisesLOW-MEDIUMC+0.811s+1 more
▼Personalis trading above TEM's $16.25 offer signals a higher required payment or deal failure, creating downside risk for TEM.
@LogicalThesisMEDIUM-HIGHA+2.212s · insight@SixSigmaCapitalMEDIUM-HIGHB-0.401s · insight@hiddensmallcapsMEDIUMB-0.773s · insight@ALEXEIMARTOVMEDIUM-HIGHA-0.743s · insight@jaysyoonMEDIUMB+1.922s · insight
▲TEM's 28.2%-33% short interest and 8.2 days to cover could force continued covering and amplify near-term upside.
@ArtofSpecuyckyMEDIUMB+0.682s · insight@MWM76LOW-MEDIUMC-1.005s@nextbigtradeMEDIUM-HIGHB+1.101s · insight@OMillionairesMEDIUM-HIGHC-1.791s@kkernttbMEDIUM-HIGHC-2.191s
▲TEM's volume-backed Stage 2 and moving-average breakout supports continuation toward $80-$100 if reclaimed levels hold.
@cevikfinanceMEDIUM-HIGHC-1.351s@stageanalysisMEDIUM-HIGHC+0.853s@enrichtradesMEDIUMC-0.622s@fundmyfundMEDIUMB-1.582s · insight@AlphaScout360LOW-MEDIUMC-4.451s@nextbigtradeMEDIUM-HIGHB+1.101s · insight+1 more
▲TEM's proprietary clinical-genomic data can become foundational infrastructure for AI-designed medicine and drive a multiyear healthcare-platform rerating.
@MisterInversorMEDIUMC+0.713s@cevikfinanceMEDIUM-HIGHC-1.352s@IncomeSharksMEDIUM-HIGHB-0.251s · insight@CaesarCapitalzLOW-MEDIUMC-0.811s@Abim4el_CarlosLOWC+1.061s
▲TEM's first quarterly GAAP profit and raised full-year guidance confirm improving operating momentum beyond the sector-driven rally.
▲Sum-of-parts, sales-multiple and platform valuations imply substantial upside, with prominent targets ranging from $80 to above $100.
@MMMTwealthMEDIUM-HIGHA-2.562s · insight@hiddensmallcapsMEDIUMB-0.771s · insight@JaguarAnalyticsMEDIUM-HIGHB+0.351s · insight@MWM76LOW-MEDIUMC-1.005s@j_dtradingLOW-MEDIUMC+0.851s
▲BTIG's Buy reiteration and price-target increase to $80 from $70 provide fresh sell-side support for TEM's rerating.
@OMillionairesMEDIUM-HIGHC-1.791s@sp3cul8rMEDIUM-HIGHB-1.111s · insight@ClassicRoyLOWC-1.521s@AIStockSavvyMEDIUMC-1.791s@BioStocksMEDIUM-HIGHC-3.021s
▼A near-term equity raise could dilute shareholders and fund Personalis obligations, offsetting strategic benefits from the acquisition.
@epictrades1MEDIUM-HIGHC+1.451s@LogicalThesisMEDIUM-HIGHA+2.211s · insight
▲Improved reimbursement could raise TEM's realized selling prices by more than 40%, materially strengthening unit economics and revenue growth.
@stocksnipaMEDIUMC-1.101s
◆After the rapid advance, resistance in the low-to-mid 70s favors consolidation, profit-taking and tighter stops before renewed upside.
@ArtofSpecuyckyMEDIUMB+0.681s · insight@zohmbasticMEDIUMC-1.383s@NirAoo7MEDIUMC-1.181s@InvestVerifiedMEDIUMC+1.571s@MarketMaestro1MEDIUM-HIGHC-2.461s
Direct calls5authors taking explicit directional positions
@JaguarAnalyticsMEDIUM-HIGHB+0.35
Targets TEM above $100 before year-end.
@ArtofSpecuyckyMEDIUMB+0.68
Buy pullbacks, add after a confirmed breakout and retest, and use 61.7 as the stop.
@MWM76LOW-MEDIUMC-1.00
Added calls across accounts and expects a rapid return to the $100 52-week high.
@pennycheckMEDIUM-HIGHA+0.57
Expects another major near-term upside leg despite TEM already rising 20%.
@ALEXEIMARTOVMEDIUM-HIGHA-0.74
Bought TEM and considers prices below 60 attractive.
Sellside activity5
BTIG pt_raise PT 80 (from 70)Maintained Buy and raised TEM's target to $80 from $70.
BTIG pt_raise PT 80Raised TEM's target to $80, with the author anticipating further upgrades and rerating.
BTIG pt_raise PT 80 (from 70)Maintained Buy and raised TEM's target to $80 from $70.
BTIG pt_raise PT 80 (from 70)Maintained Buy and raised TEM's target to $80 from $70.
BTIG pt_raise PT 80Raised its TEM price target to $80.
News / data points5discrete events + data quoted by authors
@cevikfinanceMEDIUM-HIGHC-1.35
Successful Phase 3 personalized-cancer results support MRNA, MRK and genomics-infrastructure beneficiary TEM.
@MWM76LOW-MEDIUMC-1.00
Tempus signed a definitive $1.5B agreement to acquire Personalis for $16.25 per share.
@joinautopilotMEDIUM-HIGHC-0.21
TEM reported its first quarterly GAAP profit, raised full-year guidance and rallied.
@FinanchleMEDIUMC
An aggressive buyer spent $356,300 on TEM $90 calls expiring November 20.
@ArtofSpecuyckyMEDIUMB+0.68
Short interest measured 28.2% with 8.2 days to cover, supporting continued squeeze potential.
Position disclosures3skin in the game
@MWM76LOW-MEDIUMC-1.00
Added TEM shares and increased an existing call position; also disclosed a new bullish LEAP.
@ArtofSpecuyckyMEDIUMB+0.68
Held spot and 2x exposure, raised the stop, and planned to take half profit at 74-76 before moving the stop to 68.
@hiddensmallcapsMEDIUMB-0.77
Exited TEM at $67-$68 and bought PSNL because trading above the offer increased deal risk.
Desk readconvergence assessment
The view is highly converged around clinical validation, AI-healthcare infrastructure and strong momentum, but less converged on whether the Personalis transaction creates value at the eventual price. Bullish evidence comes from several HIGH and MEDIUM-HIGH voices, while the most prolific promoter is lower-credibility @MWM76; the bear camp is smaller but includes credible A/B-grade analysts focused on concrete deal mechanics. The current SHORT book stance conflicts plainly with the dominant narrative and recent breakout; it requires Personalis repricing, dilution, or failure below technical support to overcome squeeze risk.
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 65% cheap · 9 pctile own 1y | IV/HV 0.77× (as of 2026-08-06) |
| Skew — 25Δ RR 30d | +0.010 63 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +4.42 elevated | 5-session Δ +1.08 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2025-07-30 (z=2.4) |
| Crowd state | victory-lap fade active | flagged 2026-07-02 (MC3f / MC3L exhaustion) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-16 → 2026-08-28 · now -0.04 (−1 bearish … +1 bullish)
Who spoke162
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @MWM76 | C | -1.00 | 97 | +0.69 |
| @RealHeel80 | C | -1.49 | 13 | +0.29 |
| @MisterInversor | C | +0.71 | 11 | +0.56 |
| @CaesarCapitalz | C | -0.81 | 9 | +0.67 |
| @NirAoo7 | C | -1.18 | 9 | +0.31 |
| @StockTraderHub | C | -2.19 | 9 | +0.58 |
| @cevikfinance | C | -1.35 | 8 | +0.59 |
| @hiddensmallcaps | B | -0.77 | 8 | +0.10 |
| @fundmyfund | B | -1.58 | 7 | +0.21 |
| @ALEXEIMARTOV | A | -0.74 | 6 | +0.03 |
| @SRxTrades | C | -1.52 | 6 | +0.59 |
| @ArtofSpecuycky | B | +0.68 | 6 | +0.72 |
| @PSInvestor | B | -1.48 | 5 | +0.62 |
| @beach_trades | C | -0.04 | 5 | +0.26 |
| @burak_finance | · | -0.10 | 5 | +0.66 |
| @nextbigtrade | B | +1.10 | 5 | +0.42 |
| @801010athlete | C | -0.19 | 5 | +0.32 |
| @FranVezz | C | -2.12 | 5 | -0.01 |
| @BullTradeFinder | C | +3.48 | 4 | +0.54 |
| @stageanalysis | C | +0.85 | 4 | +0.21 |
| @sp3cul8r | B | -1.11 | 4 | +0.36 |
| @Brad_E_Schulz | C | · | 4 | +0.48 |
| @KakashiCapital_ | B | -0.15 | 4 | +0.34 |
| @SelzTrades | C | +1.73 | 4 | +0.57 |
| @enrichtrades | C | -0.62 | 4 | +0.49 |
Recent signals30of 463 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @Gubloinvestor | -0.90 | Short TEM here. — Explicit immediate short call. | — | tweet ↗ |
| 2026-08-28 | @PurpleDrink_LLC | +0.35 | Recaps regime shifts favoring space, memory, oil, healthcare and software at different times | — | tweet ↗ |
| 2026-08-28 | @BCsickel | +0.35 | Directs the recipient to consider three healthcare-related stocks. | — | tweet ↗ |
| 2026-08-28 | @FranVezz | -0.45 | Recaps stops taken amid sharp declines and praises the resulting risk management. | — | tweet ↗ |
| 2026-08-28 | @PurpleDrink_LLC | +0.55 | Names TEM as the healthcare stock liked at current levels | — | tweet ↗ |
| 2026-08-28 | @ShakePryzby1 | -0.25 | Recaps successful PLTR adds and small losses in three weaker setups while discussing risk discipline. | — | tweet ↗ |
| 2026-08-28 | @PurpleDrink_LLC | -0.85 | Strongly warns against buying TEM when it becomes popular on financial social media | — | tweet ↗ |
| 2026-08-28 | @MWM76 | +0.35 | After selling most calls, the author says reloading TEM is tempting but does not commit to entry. | — | tweet ↗ |
| 2026-08-28 | @RealHeel80 | -0.20 | Author exits to cash after closing PLTR profitably and ZEC and TEM near flat. | — | tweet ↗ |
| 2026-08-28 | @KirasEpicTrades | -0.20 | Reports completed sales of the remaining CCXI and TEM shares at stated prices. | — | tweet ↗ |
| 2026-08-28 | @FranVezz | -0.15 | Recaps exiting TEM nearly flat for a 0.07% loss due to overnight risk. | — | tweet ↗ |
| 2026-08-28 | @801010athlete | -0.35 | Detailed portfolio update lists current holdings, cash, realized MRNA gains and stopped positions. | — | tweet ↗ |
| 2026-08-28 | @RealHeel80 | +0.10 | Reports being stopped for a small realized gain. | — | tweet ↗ |
| 2026-08-28 | @RealHeel80 | +0.25 | Discloses an existing position with poor cost basis and hopes for a breakout. | — | tweet ↗ |
| 2026-08-28 | @PSInvestor | +0.65 | Discloses a TEM position started in January and accumulated on dips since May. | — | tweet ↗ |
| 2026-08-28 | @GateFutures | +0.10 | Gate announces launch of leveraged stock-futures contracts for RAM, DJT and TEM. | — | tweet ↗ |
| 2026-08-27 | @StockTraderHub | +0.55 | Defines a $72 breakout watch with upside resistance and gap-fill levels at $77 and $84. | -9.4% | tweet ↗ |
| 2026-08-27 | @BoxTraderVK | +0.30 | Daily watchlist identifies bullish chart setups, earnings momentum and support conditions across six names. | -9.4% | tweet ↗ |
| 2026-08-27 | @enrichtrades | +0.10 | Tomorrow watchlist with completed gains and a COIN runner. | -9.4% | tweet ↗ |
| 2026-08-27 | @Sam_Badawi | -0.20 | Reports Cathie Wood's fund selling $4M of TEM and $3.5M of TWST. | -9.4% | tweet ↗ |
| 2026-08-27 | @FranVezz | -0.10 | Author bought TEM above prior highs and exited during the late-day reversal. | -9.4% | tweet ↗ |
| 2026-08-27 | @burak_finance | +0.50 | Promotes three completed calls with reported gains of 25%, 67% and 27%. | -9.4% | tweet ↗ |
| 2026-08-27 | @801010athlete | +0.30 | Lists current holdings and discloses a 46% cash allocation. | -9.4% | tweet ↗ |
| 2026-08-27 | @MWM76 | +0.70 | Says PSNL weakness confirms TEM's $16.25 offer will hold and calls the outcome extremely bullish for TEM. | -9.4% | tweet ↗ |
| 2026-08-27 | @fundmyfund | +0.35 | Says Tempus is performing adequately but would benefit from lower volatility. | -9.4% | tweet ↗ |
| 2026-08-27 | @OptionsFlowBoss | +0.10 | Reports repeated TEM options hits and recommends checking open interest tomorrow. | -9.4% | tweet ↗ |
| 2026-08-27 | @SRxTrades | +0.70 | Added CRCL and TEM and bought PLTR on today's breakout alongside PTIR. — Reports active additions and a new breakout purchase, supported by crypto and chart setups. | -9.4% | tweet ↗ |
| 2026-08-27 | @ChartGuys | +0.25 | Attributes a TEM stock spike to Bryan Johnson's influence | -9.4% | tweet ↗ |
| 2026-08-27 | @ChartGuys | +0.35 | Discloses continued holding contingent on support and a break above 72.96 | -9.4% | tweet ↗ |
| 2026-08-27 | @801010athlete | +0.40 | Implies TEM remains among the best opportunities and should not be abandoned for distractions. | -9.4% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.